RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells
Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
Elsevier
2024-02-01
|
| Series: | Neoplasia: An International Journal for Oncology Research |
| Subjects: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S1476558624000046 |